Eli Lilly: lung cancer drug gets approval for new indication
(CercleFinance.com) - Eli Lilly said that the US Food and Drugs Administration has approved the expanded use of its drug Alimta in combination with carboplatin and Merck's Keytruda for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
In May 2017 Merck received accelerated approval for the combination of Keytruda with Alimta and carboplatin, becoming the first combination of chemotherapy and immunotherapy to earn FDA approval for the treatment of metastatic non-squamous NSCLC.
Lung cancer is currently the leading cause of cancer death in the US.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
In May 2017 Merck received accelerated approval for the combination of Keytruda with Alimta and carboplatin, becoming the first combination of chemotherapy and immunotherapy to earn FDA approval for the treatment of metastatic non-squamous NSCLC.
Lung cancer is currently the leading cause of cancer death in the US.
Copyright (c) 2018 CercleFinance.com. All rights reserved.